Redmile Group LLC Reduces Stock Position in Repare Therapeutics Inc. (NASDAQ:RPTX)

Redmile Group LLC trimmed its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 6.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,016,302 shares of the company’s stock after selling 132,446 shares during the period. Redmile Group LLC owned about 4.75% of Repare Therapeutics worth $9,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of RPTX. SRS Capital Advisors Inc. raised its position in Repare Therapeutics by 100.0% during the 4th quarter. SRS Capital Advisors Inc. now owns 10,000 shares of the company’s stock valued at $73,000 after purchasing an additional 5,000 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in Repare Therapeutics in the fourth quarter worth about $110,000. Jump Financial LLC bought a new position in Repare Therapeutics during the 4th quarter worth about $289,000. Acadian Asset Management LLC grew its holdings in Repare Therapeutics by 53.5% during the 1st quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock worth $625,000 after acquiring an additional 46,648 shares in the last quarter. Finally, BVF Inc. IL increased its position in Repare Therapeutics by 24.6% during the 4th quarter. BVF Inc. IL now owns 10,333,600 shares of the company’s stock valued at $75,435,000 after purchasing an additional 2,041,612 shares during the period. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Stock Performance

Shares of Repare Therapeutics stock traded up $0.05 during trading on Monday, hitting $3.99. 136,818 shares of the company’s stock were exchanged, compared to its average volume of 192,795. Repare Therapeutics Inc. has a 52-week low of $2.98 and a 52-week high of $13.85. The stock has a market capitalization of $169.36 million, a price-to-earnings ratio of -3.63 and a beta of 0.73. The business has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $4.64.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.40. Repare Therapeutics had a negative return on equity of 19.81% and a negative net margin of 46.69%. The company had revenue of $52.40 million during the quarter, compared to analysts’ expectations of $34.82 million. On average, equities analysts anticipate that Repare Therapeutics Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RPTX has been the topic of a number of recent analyst reports. Bloom Burton upgraded shares of Repare Therapeutics from an “accumulate” rating to a “buy” rating in a report on Friday, April 19th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a report on Wednesday, June 5th.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.